FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

著者: Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling‐Kaiser, Salah‐Eddin Al‐Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, G. Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Jörg Hielscher, Michael Scholz, Sebastian Müller, Hartmut Link, N. Niederle, A. Rost, Heinz‐Gert Höffkes, Markus Moehler, Reinhard Udo Lindig, Dominik Paul Modest, Lisa Rossius, Thomas Kirchner, Andreas Jung, Sebastian Stintzing - The Lancet 2014 被引用: 1,741